<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03211143</url>
  </required_header>
  <id_info>
    <org_study_id>173HPS16024</org_study_id>
    <nct_id>NCT03211143</nct_id>
  </id_info>
  <brief_title>A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Multiple-dose, and Crossover Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of CKD-381 and D027 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study to compare Pharmacokinetics, Pharmacodynamics and safety of CKD-381 and D027 in
      healty subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, open-label, multiple-dose, and crossover study to compare pharmacokinetics,
      pharmacodynamics and safety of CKD-381 and D027 in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Actual">August 28, 2017</completion_date>
  <primary_completion_date type="Actual">August 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics(Area under the plasma drug concentration-time curve within a dosing interval(AUCÏ„))</measure>
    <time_frame>0h~12 h</time_frame>
    <description>Evaluating PK of Esomeprazole after Multiple dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics(Percent decrease from baseline in integrated gastric acidity for 24-hour interval after 7th dose)</measure>
    <time_frame>Baseline versus Multiple dose during 7days</time_frame>
    <description>Evaluating PD for ambulatory 24hr pH monitor</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TR group
Period 1: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days
Period 2: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RT group
Period 1: Reference drug(Nexium), 1 tablet administered before the breakfast during 7 days
Period 2: Test drug(CKD-381), 1 tablet administered before the breakfast during 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-381</intervention_name>
    <description>Test drug: CKD-381</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Esomeprazole 20mg+Sodum bicarbonate 800mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nexium</intervention_name>
    <description>Reference drug: Nexium</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <other_name>Esomeprazole magnesium trihydrate 22.3mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 19 aged and 55 aged in healthy adult

          2. Body weight more than 55kg in male, 50kg in female

          3. Body Mass Index more than 18.5 and under 25(body mass index=kg/m2)

          4. If female, must include more than one among the items

               -  The menopause(there is no natural menses for at least 2 years)

               -  Surgical Infertility(hysterectomy or bilateral oophorectomy, tubal ligation or
                  other methods of infertility condition

          5. If men has sexual life with women of childbearing age, Necessarily he agrees that use
             condoms and do not sperm donation until two months during clinical trials and after
             the final dosage of investigational products

          6. Those who fully understand about this clinical trials after enough hearing, and then
             decided to join the clinical trials by themselves and to comply with the precautions
             written consent.

        Exclusion Criteria:

          1. Have clinically significant disease that hepatobiliary system(severe hepatic
             impairment, etc), kidney(severe renal impairment, etc), nervous system, immune system,
             respiratory system, endocrine system, hemato-oncology disease, cardiovascular
             system(heart failure, etc) or mental illness, or a history of mental disease.

          2. Have a gastrointestinal disease history that can effect drug absorption(Crohn's
             disease, ulcers, etc.) or surgery(except simple appendectomy or hernia surgery)

          3. Hypersensitivity reaction or clinically significant hypersensitivity reaction in the
             history of Esomeprazole, additives or benzimidazole family

          4. Have a history of fructose intolerance, glucose-galactose malabsorbtion or sucrase
             isomaltase deficiency

          5. Defined by the following laboratory parameters

               -  Na&gt;1.5 upper limit of normal range

               -  AST, ALT&gt;1.25 upper limit of normal range

               -  Total bilirubin&gt;1.5 upper limit of normal range

               -  CPK&gt;1.5 upper limit of normal range

               -  eGFR(using by MDRD method)&lt;60mL/min/1.73m2

               -  Positive for HBV, HCV and HIV by serology test

               -  Positive by urine drug abuse test.

               -  Sitting SBP &gt; 140mmHg or &lt; 90mmHg, sitting DBP &gt; 90mmHg or &lt; 60mmHg, after 5
                  minutes break.

          6. Have a history of drug abuse

          7. Subject takes ethical drug or herbal medicine within 14 days, OTC within 7 days before
             the beginning of study treatment but investigator determine that the taking drug
             affect this study or could affect the safety of subjects.

          8. Subject who takes inhibitor and inducers of drug metabolizing enzyme(Barbiturates
             etc.) within 30 days.

          9. smoker(except the one who have stopped smoking more than 90days before beginning of
             study treatment)

         10. A heavy caffeine consumer(caffeine&gt;5 cups/day), alcohol consumer(alcohol&gt;210g/week),

         11. Taking foods containing grapefruit within 7 days before the beginning of study
             treatment(ex. Drinking containing grapefruit of 1L per a day or more within 7 days
             before the beginning of study treatment)

         12. Subject who treated with any investigational drugs within 90 days before the beginning
             of study treatment

         13. Previously donate whole blood within 60 days or component blood within 30 days.

         14. Pregnant or lactating women.

         15. An impossible one who participants in clinical trial by investigator's decision
             including laboratory test result or another reason
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choon Ok Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Trials center, Yonsei Univ. Health system</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 5, 2017</study_first_submitted>
  <study_first_submitted_qc>July 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>November 19, 2017</last_update_submitted>
  <last_update_submitted_qc>November 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GERD</keyword>
  <keyword>CKD-381</keyword>
  <keyword>Nexium</keyword>
  <keyword>Bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

